• Open the Q&A window, allowing you to ask questions to the host and panelists. It will be sent to our moderator and panelists for discussion.
• If you have a question that does not get answered today, you can contact our
, or email infoline@myeloma.org.
A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Broadcasts Tab, and then under IMF Broadcasts. A replay link will be directly emailed to all who registered for this webinar.
We Want to Hear From You!
At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey. This will also be emailed to you shortly after the workshop.
Please take a moment to complete this survey.
Ø ICELAND Updates
Ø MGUS, SMM, & DYNAMIC MODELING OF PROGRESSION
Ø FRONTLINE THERAPY
Ø MRD as EARLY RESPONSE ENDPOINT
Ø MRD in Maintenance
Ø Belantamab Drug Conjugate
Ø FasTCAR Update
Ø Teclistamab Real-World Data
Ø Role of CELMoDs
Ø The Future and Cure
80,759 participants
Active myeloma * N=28
*FLC ratio >100 or M-protein >30 g/L
3,725 with MGUS
Previously known MGUS excluded N=237
RNo further work-up
N=1,164 IMWG
Recommendations N=1,159
Intensive arm N=1,164
ØScreened MGUS NOT LINKED to Autoimmunity
Ø
Ø
MRD Neg @ 10-6 64% (Dara VRd) vs 31% (VRd)
Sonneveld P, Moreau P, Dimopoulos MA, et al. Daratumumab + bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the PERSEUS trial. Presented at: EHA 2024 Congress; June 15, 2024; Madrid, Spain
IMF Chief Scientific Officer
Dr. Brian G.M. Durie
Dr. Nikhil Munshi
(Jerome Lipper Myeloma Center, Dana -Farber Cancer Institute Boston, MA)
Dr. Jesus San Miguel
Miguel (Clinica Universidad de Navarra Pamplona, Spain)
Dr. Bruno Paiva
(CIMA Laboratory Diagnostics, University of Navarra Pamplona, Spain)
Dr. Qian Shi
The Mayo Stats Team
(Mayo Clinic Rochester, MN)
Dr. Kenneth Anderson
(Dana -Farber Cancer Institute and Harvard Medical School Boston, MA)
• Consistent high individual-patient-level correlations provide strong evidence that 9 months MRDneg-CR rate at 10-5 threshold reasonably likely predicts clinical benefit of PFS in NDTE, NDTinE and RR MM populations
‒ Promising trial-level correlations pooling 3 populations provide supportive evidence
‒ Similar results were seen for 12 months MRDneg-CR rate at 10-5 threshold
‒ Similar results were seen for OS, except in the scenarios with low events
MRDneg-CR rate classified at 10-5 threshold at 9 and 12 months IS reasonably likely to predict clinical benefit in NDTE, NDTinE, and RR MM settings
9 months MRDneg-CR Status, Classified at 10-5 Threshold
Clinical Endpoint: Progression-Free Survival
#106:
Trial
Ø 47/83 able to discontinue maintenance Ø 40 MRD negative at 10-7: 3-year PFS was 85%
5 [11%] disease progression; 6 [13%] became MRD positive at 10-6
2 developed
- Bela + Pd better than VPd Bela is back!
- Bela + Vd better than Dara + Vd
Ø FRONTLINE GCO12F .. FasT CAR T : Newly diagnosed high risk patients
Ø novel manufacturing gives * young phenotype * T cells
Ø VRd followed by CAR T as induction
Ø ORR 100 % and MRD negative @ 10-6 also 100%
Ø Well-tolerated : all CRS grade 1 or 2 within 4 days
EXCELLENT RESULTS : PFS and OS AWAITED
Ø Improved Drug Access a PRIORITY
Ø Dara/Isa VRd Frontline
Ø Early CAR T or Bispecific
Ø Establish Niche for OTHER AGENTS
Ø High-Risk Intensification
Ø Limit Treatment to 2-3 Years
ASCENT KRd-Dara: MRD Neg 84%
A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Broadcasts Tab, and then under IMF Broadcasts. A replay link will be directly emailed to all who registered for this webinar.
We Want to Hear From You!
At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey. This will also be emailed to you shortly after the workshop.
Please take a moment to complete this survey.
• Open the Q&A window, allowing you to ask questions to the host and panelists. It will be sent to our moderator and panelists for discussion.
• If you have a question that does not get answered today, you can contact our
, or email infoline@myeloma.org.
